A growing provider of specialized physical therapy services demonstrating strong profitability expansion with $781M in 2025 revenue and a 56% surge to $58M net income.
Investors should consider buying this stock due to the compelling 37% increase in net income year-over-year, signaling strong underlying business execution and pricing power. The company's ability to generate $75.1M in operating cash flow provides a solid foundation for debt reduction and potential future dividends or share buybacks once the earnings trajectory stabilizes. Consistent revenue growth from $553.1M in 2022 to $781.0M in 2025 indicates a successfully expanding market presence with room for further organic and inorganic growth.
Potential buyers should avoid this stock given the elevated debt load of $152.6M combined with a negative net change in cash of $-5.8M, which raises concerns about financial flexibility during economic downturns. The massive retained earnings deficit of $227.2M suggests historical profitability issues that have yet to fully resolve despite recent gains, creating uncertainty about long-term sustainability. High amortization expenses of $11.3M and significant interest income reliance may indicate inefficient capital allocation or heavy investment in intangible assets from past acquisitions.
U.S. Physical Therapy Inc. provides physical therapy services primarily through its flagship brand U S PHYSICAL THERAPY INC, serving the broader healthcare and rehabilitation markets with specialized clinical care. The company leverages a network of outpatient clinics to deliver musculoskeletal, sports medicine, and neurological rehabilitation programs to patients across its operational footprint. Key revenue drivers include direct patient services supported by consistent year-over-year growth in both top-line revenue and net income.
Financial performance has accelerated significantly, with 2025 net income rising to $58.0M from $45.6M in 2024, reflecting improved operational leverage and successful integration of acquired assets. Operating cash flow of $75.1M demonstrates robust liquidity management, though the company utilized $44.1M for financing activities including revolver drawdowns and repayments to manage its debt profile. The substantial goodwill balance of $692.4M requires ongoing monitoring for impairment risks as market valuations fluctuate.
The physical therapy industry is experiencing robust demand driven by an aging population, increased focus on preventative care, and post-pandemic recovery needs for musculoskeletal injuries. Competition remains fierce among independent providers and large hospital systems, yet specialized service offerings continue to command stable margins in a growing market. Regulatory environments regarding insurance coverage and licensure vary by state, requiring companies to adapt quickly to changing compliance landscapes.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $553.1M | $604.8M | $671.3M | $781.0M |
| Cost of Revenue | $441.1M | $483.3M | $547.4M | $631.3M |
| Gross Profit | $112.0M | $121.5M | $123.9M | $149.7M |
| Operating Expenses | $55.2M | $69.4M | $60.7M | $63.0M |
| Operating Income | $56.8M | $52.1M | $63.2M | $86.7M |
| G&A | $46.1M | $52.0M | $58.3M | $69.3M |
| Stock-Based Comp | $7.3M | $7.2M | $7.8M | $8.3M |
| D&A | $14.7M | $15.7M | $18.7M | $22.4M |
| Amortization | $6.5M | $7.3M | $9.5M | $11.3M |
| Other OpEx | $9.1M | $17.5M | $2.4M | $-6.2M |
| Non-Operating Income | $-1.2M | $-2.7M | $-3.0M | $-8.9M |
| Interest Income | — | $3.8M | $3.9M | $105.0K |
| Pre-Tax Income | $55.6M | $49.4M | $60.2M | $77.8M |
| Income Tax | $12.2M | $12.2M | $14.6M | $19.8M |
| Continuing Ops | $43.4M | $37.2M | $45.6M | $58.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $43.4M | $37.2M | $45.6M | $58.0M |
| Minority Interest | $11.2M | $9.0M | $14.2M | $18.4M |
| Net to Common | $32.2M | $28.2M | $31.4M | $39.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $111.3M | $233.4M | $137.6M | $140.0M |
| Cash & Equivalents | $31.6M | $152.8M | $41.4M | $35.6M |
| Accounts Receivable | $51.9M | $51.9M | $59.0M | $64.2M |
| Other Current Assets | $27.7M | $28.7M | $37.2M | $40.2M |
| Long-Term Assets | $746.9M | $763.9M | $1.03B | $1.06B |
| PP&E (Net) | $24.7M | $26.1M | $32.1M | $35.7M |
| Intangibles | $108.8M | $109.7M | $179.3M | $172.9M |
| Goodwill | $494.1M | $509.6M | $667.2M | $692.4M |
| Operating Leases | $103.0M | $103.4M | $133.9M | $144.2M |
| Other LT Assets | $16.3M | $15.1M | $17.3M | $18.9M |
| Total Assets | $858.2M | $997.2M | $1.17B | $1.20B |
| Current Liabilities | $85.5M | $102.2M | $116.3M | $139.0M |
| Current Debt | $7.9M | $7.7M | $11.0M | $9.9M |
| Current Leases | $33.7M | $35.3M | $39.8M | $42.1M |
| Other Current Liab | $6.5M | $3.9M | $5.9M | $6.1M |
| Long-Term Liabilities | $288.1M | $242.8M | $292.1M | $294.8M |
| Long-Term Debt | $175.8M | $139.0M | $142.5M | $152.6M |
| LT Operating Leases | $77.9M | $76.7M | $101.9M | $110.6M |
| Other LT Liab | $34.3M | $27.2M | $47.7M | $31.6M |
| Total Liabilities | $373.6M | $345.0M | $408.4M | $433.8M |
| Shareholders' Equity | $484.6M | $652.2M | $759.0M | $770.2M |
| Paid-In Capital | $110.3M | $281.1M | $290.3M | $285.5M |
| Retained Earnings | $232.9M | $223.8M | $227.3M | $227.2M |
| AOCI | $4.0M | $2.8M | $2.8M | $714.0K |
| Treasury Stock | $31.6M | $31.6M | $31.6M | $37.2M |
| Total L&E | $858.2M | $997.2M | $1.17B | $1.20B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $43.4M | $37.2M | $45.6M | $58.0M |
| Non-Cash Adjustments | $3.5M | $37.3M | $16.3M | $5.3M |
| Working Capital Changes | $11.6M | $7.5M | $13.0M | $11.8M |
| Cash from Operations | $58.5M | $82.0M | $74.9M | $75.1M |
| Cash from Investing | $-81.3M | $-45.0M | $-149.4M | $-36.7M |
| Debt Issuances | $150.0M | $0 | $0 | — |
| Debt Repayments | $1.9M | $3.8M | $3.8M | $9.4M |
| Share Buybacks | — | — | — | $5.6M |
| Dividends Paid | $21.3M | $24.1M | $26.5M | $27.4M |
| Cash from Financing | $25.8M | $84.3M | $-37.0M | $-44.1M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $3.0M | $121.2M | $-111.5M | $-5.8M |
| Beginning Cash | $28.6M | $31.6M | $152.8M | $41.4M |
| Ending Cash | $31.6M | $152.8M | $41.4M | $35.6M |
Revenue is derived from outpatient clinical services including orthopedics, sports medicine, and neurological rehabilitation delivered across multiple clinic locations. Growth is supported by strategic acquisitions totaling $15.7M recently, alongside organic expansion in core therapeutic offerings. Ancillary revenue streams likely include specialized equipment sales or partnerships, though primary earnings focus remains on service delivery margins of approximately 19%.
High levels of long-term debt at $152.6M create interest rate sensitivity and potential refinancing risks that could pressure operating cash flows. The company carries a significant retained earnings deficit of $227.2M, indicating historical capitalization challenges that may limit future dividend growth or M&A flexibility. Regulatory changes in healthcare reimbursement rates for physical therapy services could materially impact gross profit margins. Dependence on third-party payers and private insurance contracts introduces cyclicality to revenue streams based on payer mix shifts.
The company possesses a scalable clinic model that allows for rapid geographic expansion while maintaining consistent quality of care standards. Strong cash flow generation from operations ($75.1M) provides the liquidity needed to fund acquisitions and repay debt without diluting shareholders. A diversified service portfolio across various therapeutic specialties reduces reliance on any single medical niche, enhancing revenue stability.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.